INVESTORS & MEDIA
News Release
New Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic Dermatitis
"The data presented at AAD 2019 build upon the established body of knowledge around the efficacy and safety of Dupixent, which has been used to treat nearly 50,000 patients with inadequately controlled moderate-to-severe atopic dermatitis since its approval nearly two years ago," said
Presentations on Dupixent® (dupilumab) include results from a pooled analysis of the Phase 3 clinical trials (SOLO 1 and SOLO 2) in adult patients with moderate-to-severe atopic dermatitis and a Phase 3 trial that evaluated the efficacy and safety of Dupixent in adolescents with moderate-to-severe atopic dermatitis inadequately controlled with topical prescription therapies. Results from a real-world study of the disease and economic burden of atopic dermatitis will also be presented.
"This new information provides patients and their doctors additional insight into the impact of Dupixent on symptoms and its potential to improve quality of life in moderate-to-severe atopic dermatitis," said
Regeneron and
- Early and Sustained, Clinically Meaningful Responses With Dupilumab Treatment: A Pooled Analysis of Two Phase 3 Trials
Jerry Bagel, Mar 2/10:20-10:25/10198 - EUROSTAD Prospective Observational Study: Baseline Characteristics, Atopic Dermatitis Severity, and Patient-Reported Outcomes
Elena Rizova , Mar 2/10:05-10:10/9761 - The Economic Burden Associated With Time to Therapy Escalation for Patients With Atopic Dermatitis Uncontrolled With Topical Therapies
April W. Armstrong , Mar 2/9:05-9:10/8680 - Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial
Amy S. Paller , Mar 1-Mar 2/9:00-17:00/10051
Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4 and interleukin-13 (IL-4 and IL-13). The findings from the Dupixent trials presented at AAD in atopic dermatitis, as well as from prior trials in asthma and chronic rhinosinusitis with nasal polyps, demonstrate that both IL-4 and IL-13 are two key proteins that play a central role in type 2 inflammation, which seems to underlie atopic dermatitis as well as several other allergic diseases.
In the U.S., Dupixent is approved for treatment of adult patients with moderate-to-severe atopic dermatitis that is not well controlled by topical prescription therapies, or who cannot use topical therapies; Dupixent is also approved for use with other asthma medicines for maintenance treatment of moderate-to-severe asthma in people aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Other potential uses for Dupixent are investigational and the safety and efficacy have not been evaluated by the
Dupilumab Development Program
In addition to the currently approved indications, Regeneron and
For more information on dupilumab clinical trials please visit www.clinicaltrials.gov.
U.S. INDICATIONS
DUPIXENT is a prescription medicine used:
- to treat adults with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 18 years of age.
- with other asthma medicines for the maintenance treatment of moderate-to-severe asthma in people aged 12 years and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems. It is not known if DUPIXENT is safe and effective in children with asthma under 12 years of age.
IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS
Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.
Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:
- have eye problems (if you also have atopic dermatitis)
- have a parasitic (helminth) infection
- are taking oral, topical, or inhaled corticosteroid medicines. Do not stop taking your corticosteroid medicines unless instructed by your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine to come back.
- are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with DUPIXENT.
- are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. If you are taking asthma medicines, do not change or stop your asthma medicine without talking to your healthcare provider.
DUPIXENT can cause serious side effects, including:
- Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: breathing problems, fever, general ill feeling, swollen lymph nodes, swelling of the face, mouth and tongue, hives, itching, fainting, dizziness, feeling lightheaded (low blood pressure), joint pain, or skin rash.
- Eye problems. If you have atopic dermatitis, tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.
- Inflammation in your blood vessels: Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by DUPIXENT. Tell your healthcare provider right away if you have: rash, shortness of breath, persistent fever, chest pain, or a feeling of pins and needles or numbness of your arms or legs.
The most common side effects include injection site reactions, pain in the throat (oropharyngeal pain) and cold sores in your mouth or on your lips. Eye and eyelid inflammation, including redness, swelling and itching have been seen in patients who have atopic dermatitis.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the
Use DUPIXENT exactly as prescribed. DUPIXENT is an injection given under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give DUPIXENT injections, you or your caregiver should receive training on the right way to prepare and inject DUPIXENT. Do not try to inject DUPIXENT until you have been shown the right way by your healthcare provider. In adolescents 12 years of age and older, it is recommended that DUPIXENT be administered by or under supervision of an adult.
Please see accompanying full Prescribing Information including Patient Information.
About Regeneron
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite®technologies, such as VelocImmune®which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
About
With more than 100,000 people in 100 countries,
Regeneron Forward-Looking Statements and Use of
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although
Regeneron Contacts:
Media Relations Sharon Chen Tel: +1 (914) 847-1546 |
Investor Relations Mark Hudson Tel: +1 (914) 847-3482 |
Sanofi Contacts:
Media Relations Ashleigh Koss Tel: +1 (908) 981-8745
|
Investor Relations George Grofik Tel: +33 (0)1 53 77 45 45
|
View original content:http://www.prnewswire.com/news-releases/new-analyses-to-be-presented-at-aad-for-dupixent-dupilumab-and-the-burden-of-atopic-dermatitis-300804888.html
SOURCE